Careers                    Privacy Notice                    Terms of Use

2020 La Jolla Pharmaceutical Company

 

OUR COMPANY

La Jolla Pharmaceutical Company is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. GIAPREZA™ (angiotensin II) is approved by the U.S. Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. XERAVA™ (eravacycline) is approved by the U.S. FDA for the treatment of complicated intra-abdominal infections.

 

BOARD OF DIRECTORS

Kevin Tang
Chairman
Craig Johnson
Director
Laura Johnson
Director
David Ramsay
Director
Robert Rosen
Director

Kevin Tang

Chairman

Mr. Tang has served as a director and Chairman since August 2014. He serves as President of Tang Capital Management, LLC, a life sciences-focused investment company he founded in 2002. Mr. Tang has also served as the Chairman and Chief Executive Officer of Odonate Therapeutics, Inc. since the company’s inception in 2013. From 2009 to 2020, he served as a director of Heron Therapeutics, Inc. and, from 2012 to 2020, served as Chairman. From 2009 through its acquisition by Endo Pharmaceuticals, Inc. in 2010, Mr. Tang served as a director of Penwest Pharmaceuticals Co. In 2006, he co-founded Ardea Biosciences, Inc. and served as a director from inception through its acquisition by AstraZeneca PLC in 2012. From 2001 to 2008, Mr. Tang was a director of Trimeris, Inc. From 1993 to 2001, he held various positions at Deutsche Banc Alex Brown, Inc., an investment banking firm, most recently serving as Managing Director and head of the firm’s Life Sciences research group. Mr. Tang received a B.S. degree from Duke University.

 

Craig Johnson

Director

 

Mr. Johnson has served as a director since October 2013. He also serves as a director of Heron Therapeutics, Inc., Mirati Therapeutics, Inc. and Odonate Therapeutics, Inc. Mr. Johnson served as a director of GenomeDx Biosciences, Inc. from 2015 to 2018. He served as a director of Adamis Pharmaceuticals Corporation from 2011 to 2014 and as a director of Ardea Biosciences, Inc. from 2008 until its acquisition by AstraZeneca PLC in 2012. From 2011 to 2012, Mr. Johnson served as Chief Financial Officer of PURE Bioscience, Inc., and, from 2010 to 2011, he served as Senior Vice President and Chief Financial Officer of NovaDel Pharma Inc. From 2004 through its acquisition by Raptor Pharmaceuticals Corp. in 2009, Mr. Johnson served as Vice President and Chief Financial Officer of TorreyPines Therapeutics, Inc., and, from 2009 to 2010, as Vice President of a wholly-owned subsidiary of Raptor Pharmaceuticals Corp. From 1994 to 2004, he held various positions at MitoKor, Inc., most recently serving as Chief Financial Officer and Senior Vice President of Operations. Mr. Johnson practiced as a Certified Public Accountant with Price Waterhouse, and he received a B.B.A. degree in accounting from the University of Michigan-Dearborn.

 

 

Laura Johnson

Director

 

Ms. Johnson has served as a director since October 2013. She is the President and Chief Executive Officer of Next Generation Clinical Research Consulting, Inc., a contract research organization servicing the pharmaceutical industry that she founded in 1999. Additionally, Ms. Johnson is the President and Chief Executive Officer of Eufaeria Biosciences, Inc., a biotechnology company that she founded in 2016. Since 2018, she has served as a director of Odonate Therapeutics, Inc. Ms. Johnson is also a founder and director of SB Bancorp, Inc. and Settlers Bank, Inc. Ms. Johnson received a nursing degree from the University of the State of New York-Albany.

 

David Ramsay

Director

 

Mr. Ramsay has served as a director since September 2019. Since 2011, he has served as a director of Savara, Inc. In 2018, Mr. Ramsay served as Senior Vice President and Chief Financial Officer of Bonti, Inc. From 2003 to 2015, he held various positions at Halozyme Therapeutics, Inc., most recently serving as Chief Financial Officer. From 2000 to 2003, Mr. Ramsay served as Vice President, Chief Financial Officer of Lathian Systems, Inc. From 1998 to 2000, he served as Vice President, Treasurer and Director, Corporate Finance at Valeant Pharmaceuticals International, Inc. (formerly ICN Pharmaceuticals, Inc.). Mr. Ramsay began his career at Deloitte & Touche LLP. Mr. Ramsay received a B.S. in business administration from the University of California, Berkeley, an MBA in finance and strategic management from the Wharton School of the University of Pennsylvania and is a Certified Public Accountant (inactive) in the state of California.

Robert Rosen

Director

 

Mr. Rosen has served as a director since July 2014. Since 2017, he has served as a director of Odonate Therapeutics, Inc. From 2013 to 2019, Mr. Rosen served as President and as a director of Heron Therapeutics, Inc., and, from 2012 to 2013, served as Senior Vice President and Chief Commercial Officer of Heron Therapeutics, Inc. From 2014 to 2015, he served as a director of Conkwest, Inc. (now NantKwest, Inc.). In 2012, Mr. Rosen served as Managing Partner of Scotia Nordic LLC, a life sciences advisory firm. From 2011 to 2012, he served as Senior Vice President of Global Commercial Operations at Dendreon Corporation. From 2005 to 2011, Mr. Rosen served as Global Head of Oncology at Bayer HealthCare Pharmaceuticals. From 2002 to 2005, he was Vice President of the Oncology Business Unit at Sanofi-Synthèlabo Inc. Mr. Rosen received a B.S. degree in pharmacy from Northeastern University.

 
 
 
 
 
 

MANAGEMENT

Larry Edwards
President and Chief Executive Officer
Lakhmir Chawla, M.D.
Chief Medical Officer 
Michael Hearne
Chief Financial Officer
Stew Kroll
Chief Development Officer
Darryl Wellinghoff
Chief Commercial Officer
Luke Seikkula
Senior Vice President of Pharmaceutical Operations
Simon Cox
Vice President of Commercial Operations
Brandy Lewis
Vice President of Quality Assurance
Emily Samec
Vice President of Operations and Project Management
Mark Williams, M.D.
Vice President of Medical Affairs
Larry Edwards

President and Chief Executive Officer

 

Mr. Edwards has served as our President and Chief Executive Officer since July 2020. From 2015 to 2020, Mr. Edwards served in various positions at Tetraphase Pharmaceuticals, Inc., most recently serving as Chief Executive Officer. From 2014 to 2015, he served as Senior Director of Marketing of the Gram-negative Franchise of Cubist Pharmaceuticals, Inc. (acquired by Merck & Co., Inc.). From 1999 to 2014, Mr. Edwards served in various positions at Merck and Co., Inc., most recently serving as Global Marketing Director of Clostridium Difficile and New Infectious Disease Products. Mr. Edwards received a B.S. degree in business and healthcare administration from Ohio University.

Lakhmir Chawla, M.D.

Chief Medical Officer

 

Dr. Chawla has served as our Chief Medical Officer since July 2015. From 2014 to 2015, he served as Chief of the Division of Intensive Care Medicine at the Washington D.C. Veterans Affairs Medical Center. From 2002 to 2014, Dr. Chawla was on faculty at the George Washington University and achieved the rank of Professor of Medicine. Dr. Chawla received a B.A. degree in medical science from Boston University and an M.D. degree from Rutgers New Jersey Medical School.

Michael Hearne

Chief Financial Officer 

Mr. Hearne has served as our Chief Financial Officer since June 2020. Since 2015, he has served as Chief Financial Officer of Tang Capital Management, LLC, a life sciences-focused investment company. Since 2015, Mr. Hearne has also held various positions at Odonate Therapeutics, Inc., most recently serving as Chief Financial Officer since 2018. From 2014 to 2015, he served as a Partner at Weaver & Tidwell, LLP. Mr. Hearne started his career in public accounting at Coopers & Lybrand. Mr. Hearne received a B.S. degree in accounting and a masters of accountancy, taxation from Brigham Young University and is a Certified Public Accountant (inactive) in the state of California.

Stew Kroll

Chief Development Officer

 

Mr. Kroll has served as our Chief Development Officer since January 2020 and previously as Senior Vice President of Biometrics from 2017 to 2019. Since 2017, he has also held various positions at Odonate Therapeutics, Inc., most recently serving as Chief Development Officer since 2018. From 2005 to 2016, Mr. Kroll held various positions at Threshold Pharmaceuticals, Inc., most recently serving as Chief Operating Officer. From 2000 to 2005, he served as Senior Director of Biostatistics at Corixa Corporation. From 1997 to 2000, Mr. Kroll held various positions at Coulter Pharmaceutical, Inc., most recently serving as Director of Biostatistics. Mr. Kroll received a B.A. degree and an M.A. degree in statistics from the University of California, Berkeley.

Darryl Wellinghoff

Chief Commercial Officer

Mr. Wellinghoff has served as our Chief Commercial Officer since March 2019. From 2016 to 2018, he served as the Executive Vice President at Mainstreet Health. From 2001 to 2016, Mr. Wellinghoff held various positions at The Medicines Company, most recently serving as Senior Vice President of Americas Commercial. From 1997 to 2001, he held various commercial positions at Bristol-Myers Squibb. Mr. Wellinghoff received a B.A. degree in English from Florida State University.

Luke Seikkula

Senior Vice President of Pharmaceutical Operations

Mr. Seikkula has served as our Senior Vice President of Pharmaceutical Operations since February 2019 and previously held various positions, most recently serving as Vice President of Pharmaceutical Operations, from 2015 to 2019. From 2012 to 2015, he served as Senior Director of Materials and Logistics at Spectrum Pharmaceuticals, Inc. From 2009 to 2012, Mr. Seikkula served as Senior Director of Materials and Logistics at Allos Therapeutics, Inc. Mr. Seikkula received a B.S. degree in business administration from Winona State University and an MBA in finance from San Diego State University.

Simon Cox

Vice President of Commercial Operations

Mr. Cox has served as our Vice President of Commercial Operations since January 2020 and previously as Senior Director of Health Systems from 2018 to 2019. From 2017 to 2018, he served as Vice President of Business Development at Mainstreet Health. From 2007 to 2017, Mr. Cox held various positions at The Medicines Company, most recently serving as Vice President of Sales for the Acute Care Business Unit. Mr. Cox received a B.S. degree in biology from Clemson University.

Brandy Lewis

Vice President of Quality Assurance

Ms. Lewis has served as our Vice President of Quality Assurance since January 2020 and previously as Senior Director of Quality Assurance from 2018 to 2019. From 2017 to 2018, she served as Senior Director of Quality Assurance at Regulus Therapeutics Inc. From 2015 to 2017, Ms. Lewis served as Senior Director of Quality Assurance at Apricus Biosciences, Inc. Ms. Lewis received a B.A. degree in chemistry from the University of San Diego.

Emily Samec

Vice President of Operations and Project Management

Ms. Samec has served as our Vice President of Operations and Project Management since January 2020 and previously held various positions, most recently serving as Senior Director of Project Management, from 2016 to 2019. From 2015 to 2016, she served as Senior Director of Regulatory Affairs at Pfenex, Inc. From 2012 to 2015, Ms. Samec served as Senior Director of Regulatory Services at GlobalSubmit. In 2012, she served as Director of Regulatory Operations at Ardea Biosciences, Inc. Ms. Samec received a B.A. degree in art history from San Diego State University.

Mark Williams, M.D.

Vice President of Medical Affairs

Dr. Williams has served as our Vice President of Medical Affairs since January 2020 and previously held various positions, most recently serving as Senior Global Medical Director, from 2017 to 2019. From 2015 to 2016, he served as Chief Medical Officer at Asahi Kasei Pharma America. From 2013 to 2015, Dr. Williams served as Field Medical Director at Astute Medical, Inc. From 2011 to 2012, he served as Chief Medical Officer at BioCritica, Inc. From 2001 to 2010, Dr. Williams held various positions at Eli Lilly and Company, most recently serving as Global Medical Director of Critical Care Research. Dr. Williams received a B.S. degree in biology from Indiana University and an M.D. degree from Indiana University.

 
 
 
 
 
 
 
 
 
 

2020 La Jolla Pharmaceutical Company

Careers                    Privacy Notice                    Terms of Use